{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:39:56Z","timestamp":1773153596931,"version":"3.50.1"},"reference-count":147,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1378\/chest.08-0673","type":"journal-article","created":{"date-parts":[[2008,6,23]],"date-time":"2008-06-23T23:37:53Z","timestamp":1214264273000},"page":"234S-256S","source":"Crossref","is-referenced-by-count":187,"special_numbering":"S","title":["New Antithrombotic Drugs"],"prefix":"10.1016","volume":"133","author":[{"given":"Jeffrey I.","family":"Weitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meyer M.","family":"Samama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1378\/chest.08-0673_bib1","series-title":"Hemostasis and thrombosis: basic principles and clinical practice","first-page":"1123","article-title":"The structure of thrombi","author":"Freiman","year":"1987"},{"key":"10.1378\/chest.08-0673_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0673_bib3","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/jama.292.15.1867","article-title":"Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease","volume":"292","author":"Tran","year":"2004","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0673_bib4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0673_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/138161206775193064","article-title":"Aspirin resistance: definitions, mechanisms, prevalence and clinical significance","volume":"12","author":"Macchi","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1378\/chest.08-0673_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2006.10.040","article-title":"Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review","volume":"153","author":"Hovens","year":"2007","journal-title":"Am Heart J"},{"key":"10.1378\/chest.08-0673_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2005-869523","article-title":"Clopidogrel and ticlopidine: p2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis","volume":"31","author":"Savi","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.08-0673_bib8","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib9","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2174\/138161206776361345","article-title":"Clopidogrel resistance: implications for coronary stenting","volume":"12","author":"Gurbel","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1378\/chest.08-0673_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1055\/s-2007-969034","article-title":"Variable response to clopidogrel in patients with coronary artery disease","volume":"33","author":"Geisler","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.08-0673_bib11","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.105.559088","volume":"112","author":"Von Beckerath","year":"2005","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib12","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib13","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/eurheartj\/ehi074","article-title":"Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?","volume":"26","author":"Kapetanakis","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.08-0673_bib15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0673_bib16","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0673_bib17","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0673_bib18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1378\/chest.126.2.501","article-title":"Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points","volume":"126","author":"Turpie","year":"2004","journal-title":"Chest"},{"key":"10.1378\/chest.08-0673_bib19","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/bjs.5154","article-title":"Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery","volume":"92","author":"Agnelli","year":"2005","journal-title":"Br J Surg"},{"key":"10.1378\/chest.08-0673_bib20","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0673_bib21","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"Buller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0673_bib22","first-page":"1461","volume":"354","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0673_bib23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1160\/TH06-05-0234","article-title":"Emerging anticoagulants for the treatment of venous thromboembolism","volume":"96","author":"Weitz","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib24","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1055\/s-0037-1615759","article-title":"SR123781A, a synthetic heparin mimetic","volume":"85","author":"Herbert","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00002018-200528040-00006","article-title":"Hepatic findings in long-term clinical trials of ximelagatran","volume":"28","author":"Lee","year":"2005","journal-title":"Drug Saf"},{"key":"10.1378\/chest.08-0673_bib26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.cct.2006.04.005","article-title":"The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee","volume":"27","author":"Boudes","year":"2006","journal-title":"Contemp Clin Trials"},{"key":"10.1378\/chest.08-0673_bib27","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/j.1538-7836.2005.01468.x","article-title":"The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies","volume":"3","author":"Gaussem","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib28","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0735-1097(03)00048-2","article-title":"Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin","volume":"41","author":"Belhassen","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.08-0673_bib29","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1517\/13543784.15.12.1627","article-title":"Prasugrel","volume":"15","author":"Tantry","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1378\/chest.08-0673_bib30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.CIR.0000112378.09325.F9","article-title":"Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance","volume":"109","author":"Lau","year":"2004","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2174\/138161206776361354","article-title":"Thienopyridines and statins: assessing a potential drug-drug interaction","volume":"12","author":"Neubauer","year":"2006","journal-title":"Curr Pharm Res"},{"key":"10.1378\/chest.08-0673_bib32","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2125.2006.02792.x","article-title":"A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y(12) inhibitor, compared with clopidogrel in healthy humans","volume":"63","author":"Jakubowski","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.08-0673_bib34","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","article-title":"Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial","volume":"111","author":"Wiviott","year":"2005","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib35","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0673_bib36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-2005-869525","article-title":"Preclinical and clinical studies with selective reversible direct P2Y12 antagonists","volume":"31","author":"Van Giezen","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.08-0673_bib37","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1345\/aph.1G120","article-title":"Cangrelor for treatment of coronary thrombosis","volume":"40","author":"Fugate","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1378\/chest.08-0673_bib38","doi-asserted-by":"crossref","first-page":"689.e1","DOI":"10.1016\/j.ahj.2005.11.014","article-title":"Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial","volume":"151","author":"Greenbaum","year":"2006","journal-title":"Am Heart J"},{"key":"10.1378\/chest.08-0673_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/13543784.16.2.225","article-title":"AZD6140","volume":"16","author":"Tantry","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1378\/chest.08-0673_bib40","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.08-0673_bib41","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1742-1241.2007.01294.x","article-title":"Dyspnoea after antiplatelet agents: the AZD6140 controversy","volume":"61","author":"Serebruany","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1378\/chest.08-0673_bib42","first-page":"1","article-title":"Peptide-derived protease-activated receptor-1 (PAR-1) antagonists","volume":"1","author":"Seiler","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1378\/chest.08-0673_bib43","first-page":"37","article-title":"Potent non-peptide thrombin receptor antagonists","volume":"1","author":"Chackalamannil","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1378\/chest.08-0673_bib44","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1097\/00003246-200111000-00007","article-title":"Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study","volume":"29","author":"Abraham","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1378\/chest.08-0673_bib45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"Abraham","year":"2003","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0673_bib46","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1073\/pnas.92.13.6152","article-title":"Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa","volume":"92","author":"Cappello","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1378\/chest.08-0673_bib47","doi-asserted-by":"crossref","first-page":"10063","DOI":"10.1074\/jbc.M009116200","article-title":"Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2","volume":"276","author":"Bergum","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0673_bib48","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1160\/TH03-05-0265","article-title":"Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man: dependence on the stoichiometric binding to circulating factor X","volume":"90","author":"Vlasuk","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib49","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/hc2601.091386","article-title":"Dose-response study of recombinant factor VIIa\/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement","volume":"104","author":"Lee","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib50","unstructured":"Giugliano RP, Wiviott SD, Morrow DA, et al. Addition of a tissue-factor\/factor VIIa inhibitor to standard treatments in NSTE-ACS managed with an early invasive strategy: results of the Phase II ANTHEM-TIMI 32 double-blind randomized clinical trial [abstract]. Program and Abstracts of the American Heart Association Meeting, Dallas, TX, November, 2005:2095\/C16"},{"key":"10.1378\/chest.08-0673_bib51","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/S0735-1097(03)00478-9","article-title":"Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor\/factor VIIa complex, in patients undergoing elective coronary angioplasty","volume":"41","author":"Moons","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.08-0673_bib52","first-page":"83","article-title":"Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon","volume":"26","author":"Taylor","year":"1996","journal-title":"Haemostasis"},{"key":"10.1378\/chest.08-0673_bib53","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1161\/01.CIR.92.10.3041","article-title":"Influence of blockade at specific levels of the coagulant cascade on restenosis in a rabbit atherosclerotic femoral artery injury model","volume":"92","author":"Jang","year":"1995","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib54","first-page":"312","volume":"36","author":"Lincoff","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.08-0673_bib55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature00963","article-title":"RNA aptamers as reversible antagonists of coagulation factor IXa","volume":"419","author":"Rusconi","year":"2002","journal-title":"Nature"},{"key":"10.1378\/chest.08-0673_bib56","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.668434","article-title":"First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity","volume":"114","author":"Dyke","year":"2006","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib57","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ymthe.2006.04.006","article-title":"A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery","volume":"14","author":"Nimjee","year":"2006","journal-title":"Mol Ther"},{"key":"10.1378\/chest.08-0673_bib58","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003495-200666110-00001","article-title":"Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopedic surgery","volume":"66","author":"Eriksson","year":"2006","journal-title":"Drugs"},{"key":"10.1378\/chest.08-0673_bib59","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.V97.8.2308","article-title":"Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex","volume":"97","author":"Rezaie","year":"2001","journal-title":"Blood"},{"key":"10.1378\/chest.08-0673_bib60","doi-asserted-by":"crossref","first-page":"17663","DOI":"10.1074\/jbc.M011586200","article-title":"The use of prothrombin (S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation","volume":"276","author":"Brufatto","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0673_bib61","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1021\/bi00191a017","article-title":"Assembly of the prothrombinase complex enhances the inhibition of bovine factor Xa by tick anticoagulant peptide","volume":"33","author":"Krishnaswamy","year":"1994","journal-title":"Biochemistry"},{"key":"10.1378\/chest.08-0673_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3565(24)36988-5","article-title":"Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase","volume":"283","author":"Herault","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1378\/chest.08-0673_bib63","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1055\/s-0038-1649967","article-title":"Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107\/ORG31540) with high affinity to antithrombin III in man","volume":"74","author":"Boneu","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib64","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial","volume":"332","author":"Cohen","year":"2006","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0673_bib65","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0673_bib66","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","article-title":"Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"10.1378\/chest.08-0673_bib67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1538-7836.2003.00516.x","volume":"2","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib68","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"Buller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0673_bib69","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa067703","article-title":"Extended prophylaxis of venous thromboembolism with idraparinux","volume":"357","author":"Buller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0673_bib70","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1055\/s-0037-1615759","article-title":"SR123781A, a synthetic heparin mimetic","volume":"85","author":"Herbert","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib71","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1074\/jbc.274.10.6226","article-title":"Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II","volume":"274","author":"Becker","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0673_bib72","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1046\/j.1538-7836.2003.00358.x","article-title":"Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot-bound thrombin and factor Xa in vitro and in vivo","volume":"1","author":"Herault","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib73","first-page":"1030","article-title":"DX-9065a, a novel synthetic, selective and orally active inhibitor of Factor Xa: in vitro and in vivo studies","volume":"276","author":"Herbert","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1378\/chest.08-0673_bib74","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0009-9236(99)70033-0","article-title":"Tolerability, pharmacokinetics and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific Factor Xa inhibitor, in healthy male volunteers","volume":"66","author":"Maruyama","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-0673_bib75","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.thromres.2005.03.017","article-title":"Effect of the novel direct Factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease","volume":"117","author":"Becker","year":"2006","journal-title":"Thromb Res"},{"key":"10.1378\/chest.08-0673_bib76","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1538-7836.2004.01081.x","article-title":"First experience with direct, selective Factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial","volume":"3","author":"Alexander","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib77","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1538-7933.2004.00594.x","article-title":"Initial experience with factor Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI pilot","volume":"2","author":"Alexander","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib78","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1160\/TH05-05-0347","article-title":"Pharmcodynamic markers in the early clinical assessment of otamixaban, a direct Factor Xa inhibitor","volume":"94","author":"Paccaly","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib79","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.clpt.2006.09.002","article-title":"Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease","volume":"80","author":"Hinder","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-0673_bib80","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1161\/CIRCULATIONAHA.106.653428","article-title":"Randomized, double-blind, dose-ranging study of otamixaban, a novel, paternal, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial","volume":"115","author":"Cohen","year":"2007","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib81","first-page":"15a","article-title":"A Phase II randomized, double blind, five-arm, parallel group, dose-response study of a new oral directly acting Factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery [abstract 41]","volume":"102","author":"Lassen","year":"2003","journal-title":"Blood"},{"key":"10.1378\/chest.08-0673_bib82","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood.V108.11.910.910","article-title":"Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor [abstract]","volume":"108","author":"Kan","year":"2006","journal-title":"Blood"},{"key":"10.1378\/chest.08-0673_bib83","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib84","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics of BAY 59-7939, an oral, direct Factor Xa inhibitor, after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmcol"},{"key":"10.1378\/chest.08-0673_bib85","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.thromres.2006.12.025","article-title":"Dose-escalation study of rivaroxaban (BAY 59-7939), an oral, direct Factor Xa inhibitor, for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"120","author":"Eriksson","year":"2007","journal-title":"Thromb Res"},{"key":"10.1378\/chest.08-0673_bib86","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","article-title":"Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement","volume":"4","author":"Eriksson","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib87","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","article-title":"BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement; a phase II dose-ranging study","volume":"3","author":"Turpie","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib88","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH07-01-0055","article-title":"Rivaroxaban for thromboprophylaxis after orthopedic surgery: pooled analysis of two studies","volume":"97","author":"Fisher","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib89","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.106.642074","article-title":"A once daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement","volume":"114","author":"Eriksson","year":"2006","journal-title":"Circulation"},{"issue":"suppl 2","key":"10.1378\/chest.08-0673_bib90","first-page":"O-S-006B","article-title":"Late breaking clinical trial: rivaroxaban, an oral, direct factor Xa inhibitor, for the prevention of venous thromboembolism in total knee replacement surgery: results of the RECORD-3 study\u2013late breaking [abstract]","volume":"5","author":"Lassen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib91","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"issue":"suppl","key":"10.1378\/chest.08-0673_bib92","first-page":"761","article-title":"Once-daily treatment with an oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), in patients with acute, symptomatic deep vein thrombosis: the EINSTEIN-DVT dose-finding study [abstract P4568]","volume":"27","author":"Buller","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.08-0673_bib93","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1538-7836.2007.02436.x","article-title":"A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement","volume":"5","author":"Agnelli","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib94","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1538-7836.2007.02644.x","article-title":"A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib95","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","article-title":"Oral direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases","volume":"27","author":"Turpie","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"suppl 2","key":"10.1378\/chest.08-0673_bib96","first-page":"P-T-652","article-title":"Evaluation of the factor Xa (FXa) inhibitor, PRT054021 (PRT021), against enoxaparin in a randomized trial for the prevention of venous thromboembolic events after total knee replacement (EXPERT) [abstract]","volume":"5","author":"Turpie","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib97","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0673_bib98","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa050935","article-title":"Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death","volume":"353","author":"Abraham","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0673_bib99","doi-asserted-by":"crossref","first-page":"12602","DOI":"10.1016\/S0021-9258(19)38386-3","article-title":"Stable expression of a secretable deletion mutation of recombinant human thrombomodulin in mammalian cells","volume":"265","author":"Parkinson","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0673_bib100","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1538-7836.2005.01251.x","article-title":"Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement","volume":"3","author":"Kearon","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib101","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/hc0802.104331","article-title":"Direct thrombin inhibitors in acut coronary syndromes: present and future","volume":"105","author":"Weitz","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib102","doi-asserted-by":"crossref","first-page":"V275","DOI":"10.1016\/S0049-3848(02)00093-2","article-title":"Direct thrombin inhibitors","volume":"106","author":"Weitz","year":"2002","journal-title":"Thromb Res"},{"key":"10.1378\/chest.08-0673_bib103","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1055\/s-2001-16889","article-title":"Production and clinical development of a Hansenula polymorpha- derived PEGylated hirudin","volume":"27","author":"Avgerinos","year":"2001","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.08-0673_bib104","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/j.1538-7836.2006.02064.x","article-title":"A comparison of the \u03b2-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis","volume":"4","author":"Tommey","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"suppl 2","key":"10.1378\/chest.08-0673_bib105","first-page":"P-M-653","article-title":"A phase II double-blind placebo-controlled parallel-group randomized study of extended prophylaxis with odiparcil following total hip arthroplasty (THA) [abstract]","volume":"5","author":"Bates","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib106","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","article-title":"The direct thrombin inhibitor melagatran and its oral prodrug H376\/95: intestinal absorption properties, biochemical and pharmacodynamic effects","volume":"101","author":"Gustafsson","year":"2001","journal-title":"Thromb Res"},{"key":"10.1378\/chest.08-0673_bib107","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijcard.2006.11.041","article-title":"Ximelagatran\/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients","volume":"122","author":"Testa","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1378\/chest.08-0673_bib108","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00002018-200528040-00006","article-title":"Hepatic findings in long-term clinical trials of ximelagatran","volume":"28","author":"Lee","year":"2005","journal-title":"Drug Saf"},{"key":"10.1378\/chest.08-0673_bib109","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2796.2003.01225.x","article-title":"Oral direct thrombin inhibitors in clinical development","volume":"254","author":"Gustafsson","year":"2003","journal-title":"J Int Med"},{"key":"10.1378\/chest.08-0673_bib110","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1160\/TH06-05-0234","article-title":"Emerging anticoagulants for the treatment of venous thromboembolism","volume":"96","author":"Weitz","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib111","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.08-0673_bib112","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","article-title":"A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial","volume":"3","author":"Eriksson","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib113","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib114","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1378\/chest.08-0673_bib115","first-page":"O-W-050","article-title":"The oral direct thrombin inhibitor, dabigatran etexilate, is effective and safe for prevention of major venous thromboembolism following major orthopedic surgery [abstract]","volume":"5","author":"Caprini","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib116","first-page":"482","article-title":"Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation: a dose finding trial with comparison to warfarin [abstract]","volume":"26","author":"Wallentin","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.08-0673_bib117","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1055\/s-0038-1649642","article-title":"Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil","volume":"70","author":"Fujii","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib118","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/01.CIR.92.4.767","article-title":"Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin: a potential link between lipid lowering and fibrinolysis","volume":"92","author":"Brown","year":"1995","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib119","doi-asserted-by":"crossref","first-page":"27942","DOI":"10.1074\/jbc.270.46.27942","article-title":"The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A","volume":"270","author":"Kvassman","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0673_bib120","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1172\/JCI117937","article-title":"Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro","volume":"95","author":"Eitzman","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.08-0673_bib121","first-page":"916","article-title":"Low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits","volume":"96","author":"Friederich","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib122","doi-asserted-by":"crossref","first-page":"14477","DOI":"10.1074\/jbc.272.22.14477","article-title":"On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B","volume":"272","author":"Sakharov","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0673_bib123","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1161\/01.CIR.93.7.1328","article-title":"Inducible carboxypeptidase activity: a role in clot lysis in vivo","volume":"93","author":"Redlitz","year":"1996","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0673_bib124","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood.V94.8.2735.420k30_2735_2743","article-title":"A novel approach to arterial thrombolysis","volume":"94","author":"Klement","year":"1999","journal-title":"Blood"},{"key":"10.1378\/chest.08-0673_bib125","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0049-3848(00)00184-5","article-title":"An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model","volume":"98","author":"Nagashima","year":"2000","journal-title":"Thromb Res"},{"key":"10.1378\/chest.08-0673_bib126","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1160\/TH06-04-0197","article-title":"Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI)","volume":"96","author":"Guimaraes","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib127","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.bmcl.2006.11.078","article-title":"3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa)","volume":"17","author":"Islam","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1378\/chest.08-0673_bib128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1538-7836.2003.00028.x","article-title":"Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis","volume":"1","author":"Schneider","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib129","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1074\/jbc.M205006200","article-title":"Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro","volume":"278","author":"Walker","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0673_bib130","first-page":"177","article-title":"The roles of fibrinogen and fibrin in hemostasis and thrombosis","volume":"29","author":"Mosesson","year":"1992","journal-title":"Semin Hematol"},{"key":"10.1378\/chest.08-0673_bib131","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/10408369609084691","article-title":"Novel aspects of blood coagulation factor XIII: I. Structure, distribution, activation, and function","volume":"33","author":"Muszbek","year":"1996","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1378\/chest.08-0673_bib132","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1055\/s-0038-1656085","article-title":"Tridegin, a novel peptidic inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro","volume":"77","author":"Seale","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib133","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1042\/bj3240797","article-title":"Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii","volume":"324","author":"Finney","year":"1997","journal-title":"Biochem J"},{"key":"10.1378\/chest.08-0673_bib134","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00001721-199102000-00025","article-title":"Destabilase, the novel epsilon-(gamma-Glu)-Lys isopeptidase with thrombolytic activity","volume":"2","author":"Baskova","year":"1991","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.08-0673_bib135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s004380050291","article-title":"Genes from the medicinal leech (Hirudo medicinalis) coding for unusual enzymes that specifically cleave endo-epsilon (gamma-Glu)-Lys isopeptide bonds and help to dissolve blood clots","volume":"253","author":"Zavalova","year":"1996","journal-title":"Mol Gen Genet"},{"key":"10.1378\/chest.08-0673_bib136","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2165\/00003495-199652040-00012","article-title":"Reteplase: a review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction","volume":"52","author":"Noble","year":"1996","journal-title":"Drugs"},{"key":"10.1378\/chest.08-0673_bib137","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00129784-200101010-00006","article-title":"Tenetecplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction","volume":"1","author":"Dunn","year":"2001","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1378\/chest.08-0673_bib138","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/jama.286.4.442","article-title":"Bolus fibrinolytic therapy in acute myocardial infarction","volume":"286","author":"Llevadot","year":"2001","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0673_bib139","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/14712598.6.12.1361","article-title":"Alfimeprase: a novel recombinant direct-acting fibrinolytic","volume":"6","author":"Deitcher","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1378\/chest.08-0673_bib140","first-page":"141","article-title":"Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis","volume":"31","author":"Toombs","year":"2001","journal-title":"Haemostasis"},{"key":"10.1378\/chest.08-0673_bib141","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.2006.05.8438","article-title":"Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices","volume":"24","author":"Moll","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1378\/chest.08-0673_bib142","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1538-7836.2004.01087.x","article-title":"Thrombolytic activity of BB-10153, a thrombin-activatable plasminogen","volume":"3","author":"Comer","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib143","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1538-7836.2005.01352.x","article-title":"Pharmacokinetics and pharmacodynamics of BB-10153, a thrombin-activatable plasminogen, in healthy volunteers","volume":"3","author":"Curtis","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib144","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11239-006-8080-1","article-title":"Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial","volume":"22","author":"Gibson","year":"2006","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0673_bib145","doi-asserted-by":"crossref","first-page":"18292","DOI":"10.1074\/jbc.273.29.18292","article-title":"Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E","volume":"273","author":"Stewart","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0673_bib146","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1055\/s-0038-1653800","article-title":"Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model","volume":"73","author":"Mellott","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0673_bib147","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1161\/01.STR.0000149938.08731.2c","article-title":"The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase","volume":"36","author":"Hacke","year":"2005","journal-title":"Stroke"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369208601191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369208601191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T20:53:52Z","timestamp":1738270432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369208601191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":147,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0012369208601191"],"URL":"https:\/\/doi.org\/10.1378\/chest.08-0673","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}